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Pardioprotective Effects of
ranulocyte Colony-Stimulating Factor
n Swine With Chronic Myocardial Ischemia
iroshi Hasegawa, MD, PHD, Hiroyuki Takano, MD, PHD, Koji Iwanaga, DVM,
asashi Ohtsuka, MD, PHD, Yingjie Qin, MD, Yuriko Niitsuma, MD, Kazutaka Ueda, MD,
omohiko Toyoda, MD, PHD, Hiroyuki Tadokoro, MD, Issei Komuro, MD, PHD
hiba, Japan
OBJECTIVES The aim of this study was to investigate the effect of granulocyte colony-stimulating factor
(G-CSF) on chronic myocardial ischemia in swine.
BACKGROUND We recently have reported that G-CSF prevents cardiac remodeling and dysfunction after
acute myocardial infarction in mice and swine. It remains unclear whether G-CSF has
beneficial effects on chronic myocardial ischemia.
METHODS An ameroid constrictor was placed on left circumflex coronary artery of swine. The presence
of myocardial ischemia was verified at four weeks after the operation, and the animals were
randomly assigned into the following two groups: 1) administration of vehicle (control
group, n  10), and 2) administration of G-CSF (10 g/kg/day) for seven days (G-CSF
group, n  10).
RESULTS Echocardiographic examination revealed that the G-CSF treatment prevented left ventricular
dilation and dysfunction at eight weeks after the operation. Stress echocardiography revealed
that G-CSF ameliorated the regional contractility of chronic myocardial ischemia. Morpho-
logical analysis revealed that the extent of myocardial fibrosis of the ischemic region was less
in the G-CSF group than in control group. There were more vessels and less apoptotic cells
at the ischemic region of the heart of the G-CSF group than control group. Moreover, Akt1
was more strongly activated in the heart of the G-CSF group than control group.
CONCLUSIONS These findings suggest that G-CSF improves cardiac function of chronic myocardial ischemia
through decreases in fibrosis and apoptotic death and an increase in vascular density in the
ischemic region. (J Am Coll Cardiol 2006;47:842–9) © 2006 by the American College of























tschemic cardiomyopathy is a leading cause of congestive heart
ailure in many countries (1). In chronic myocardial ischemia,
ontractile function is depressed because of reduced myocardial
erfusion (2). The viable-but-dysfunctional myocardium could
e reversed by the restoration of myocardial blood flow
3–8). Although interventional therapies such as coronary
rtery bypass grafting and percutaneous coronary interven-
ion are performed to increase blood supply to ischemic
egion, many patients with ischemic cardiomyopathy cannot
e treated because of severe and diffuse coronary atheroscle-
osis. The only possibility is pharmacological therapy, which
educes myocardial oxygen demand to treat chronic myo-
ardial ischemia if interventional therapies cannot be feasi-
le. Therefore, novel strategies in patients with severe
yocardial ischemia not amenable to conventional revascu-
arization have been awaited.
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005, accepted September 26, 2005.Granulocyte colony-stimulating factor (G-CSF), a hemato-
oietic cytokine, induces the mobilization of hematopoietic
tem cells and endothelial progenitor cells (EPCs) from bone
arrow into the peripheral blood circulation (9–11). Recently,
everal groups, including ours, have reported that G-CSF
revents left ventricular (LV) remodeling after acute myocar-
ial infarction (MI) in mice and swine (12–17). We have
emonstrated that G-CSF receptor is expressed on cardiomy-
cytes and that G-CSF prevents LV remodeling after MI by
ctivating the Janus family tyrosine kinases and signal trans-
ucer and activator of transcription pathway in cardiomyocytes
17). In the present study, we examined whether G-CSF
reatment is effective on chronic myocardial ischemia in swine
nd investigated the mechanism of beneficial effects of G-CSF.
ETHODS
wine model of chronic myocardial ischemia. Male
orkshire swine (Science Breeding Farm, Iwate, Japan)
eighing 15 to 20 kg were used to induce chronic myocar-
ial ischemia. Ameroid-induced progressive coronary occlu-
ion was performed as described previously (18–20). Briefly,
nitial sedation was achieved with intramuscularly ketamine
nd xylazine. An ear vein was then cannulated for admin-
stration of an infusion of ketamine and thiamylal as needed
o supplemental anesthesia. The swine was intubated and
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February 21, 2006:842–9 Effects of G-CSF on Chronic Myocardial Ischemiaconcentration of 2.0%. Isoflurane was the primary anes-
hetic agent. After opening the chest, an ameroid constrictor
2.5 mm of internal diameter) was implanted around the
roximal left circumflex coronary artery (LCX). The chronic
yocardial ischemia was induced by progressive coronary
rtery stenosis with ameroid coronary constriction (21). All
rotocols were approved by the Institutional Animal Care
nd Use Committee of the Chiba University.
ytokine treatment. Ameroid constrictors were implanted
n 58 pigs. Twenty-three pigs died suddenly within three
eeks of the implantation, possibly because of abrupt
oronary occlusion or lethal arrhythmia. Four weeks after
he implantation of ameroid constrictors, all surviving pigs
n  35) underwent the following: 1) transthoracic echo-
ardiography, 2) cardiac catheter study, and 3) selective left
nd right coronary artery angiography. Twenty swine of 35
hat developed severe coronary stenosis and suffered from
yocardial ischemia without MI were assigned randomly by
n investigator (who was different from operators) into: 1) a
ontrol group (n  10), which was injected subcutane-
usly with saline for seven days, or 2) G-CSF treatment
roup (n  10), which was injected subcutaneously with
ecombinant human G-CSF (10 g/kg/day, Kirin Brewery
o. LTD., Tokyo, Japan) for seven days. Five pigs served as
ham-operated controls in which the constrictor was not
mplanted after opening the chest. The numbers of circu-
ating white blood cells and granulocytes were counted
efore and at four and eight weeks after the operation in
oth groups. We also measured the serum levels of creatine
inase-MB isoenzyme and cardiac troponin I before and at
ne and four weeks after the operation in both groups.
chocardiography. Echocardiographic studies were per-
ormed before surgery and at four and eight weeks after the
lacement of ameroid constrictors with Philips Sonos 5500
nd an ultraband S4 sector transducer (Philips Medical Sys-
ems N.A., Bothell, Washington). Two-dimensional epicar-
ial echocardiography was performed at the short-axis view at
Abbreviations and Acronyms
DOB  dobutamine
ECs  endothelial cells
EPC  endothelial progenitor cell
FAC  fractional area change
G-CSF  granulocyte colony-stimulating factor
LCX  left circumflex coronary artery
LV  left ventricle
LVEDA  left ventricular end-diastolic area
LVEDP  left ventricular end-diastolic pressure
LVESA  left ventricular end-systolic area
MI  myocardial infarction
TUNEL  terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate-
digoxigenin nick end labeling
VEGF  vascular endothelial growth factor
vWF  von Willebrand factoridpapillary muscle level of LV (22). Images were obtained from the epicardial surface of the right ventricle and recorded
n a magnetic optical drive and video tape for offline analysis of
all thickening. Left ventricular end-diastolic area (LVEDA),
eft ventricular end-systolic area (LVESA), interventricular
eptum wall thickness in diastole, LV posterior wall thickness
n diastole, and fractional area change (FAC) were measured
y B-mode. The end-diastolic frame of the echocardiographic
mages was selected using the onset of the Q-wave of the
lectrocardiography; the frame with the smallest LV cavity was
efined as end-systole. Regional contractility (fractional short-
ning) was obtained by measuring the percent wall thickening
end-systolic thickness minus end-diastolic thickness/end-
iastolic thickness) of the ischemic (LCX) region 100 (23).
tress echocardiography was performed with incremental doses
f dobutamine (DOB) infusion from 5 to 40  at 5-min
ntervals. All measurements were performed at rest and under
tress with 10 g/kg/min (10 ) and 40 g/kg/min (40 ) of
OB to document the presence of hibernating myocardium in
CX region. The average of three measurements in each
xamined region was used for analysis. The recording of
chocardiography and its evaluation were performed by differ-
nt persons blinded to randomization.
ardiac catheter study. Four and eight weeks after ameroid
onstrictor implantation, cardiac catheter study was performed.
6-F sheath introducer was inserted via left carotid artery and
pig-tail catheter was implanted in the LV cavity through a
heath introducer to obtain left ventricular end-diastolic pres-
ure (LVEDP), dp/dt, and dp/dt. Coronary angiography
as performed subsequently.
istological analysis. After the echocardiography and cor-
nary angiography, the swine were sacrificed. After heart
eight was measured, ischemic (LCX region) and nonisch-
mic (remote region) myocardium were fixed with perfusion of
.8% formaldehyde, embedded in paraffin for hematoxylin-
osin staining and van Gieson staining, or embedded in OCT
ompound for immunohistochemistry. To determine the
egree of collagen fiber accumulation, we calculated the
atio of van Gieson staining fibrosis area to total myocar-
ium area with the software NIH IMAGE 1.63 (National
nstitutes of Health, Bethesda, Maryland) for image analy-
is. The rest of myocardium was frozen and prepared for
estern blot analysis. Endothelial cells (ECs) were identi-
ed immunohistochemically using anti-von Willebrand fac-
or (vWF) antibody (Dako, Carpinteria, California) and
y3-labeled secondary antibody. To count the numbers of
essels, 15 fields were chosen randomly from ischemic and
onischemic regions in each sample (n  10 each group).
or detection of apoptotic cells, the terminal deoxynucleo-
idyl transferase-mediated deoxyuridine triphosphate-
igoxigenin nick end labeling (TUNEL) assay was per-
ormed using the In Situ Apoptosis Detection Kit (Takara,
apan). To identify which cells were TUNEL-positive, we
erformed double-staining by using anti-cardiac troponin T
r anti-vWF antibody with TUNEL assay.
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Effects of G-CSF on Chronic Myocardial Ischemia February 21, 2006:842–9yocardium of operated swine and subjected to Western
lot analysis. The extracts were centrifuged at 14,000 rpm at
°C for 30 min, and the total protein concentration was
easured with the BCA protein assay kit (Pierce, Illinois).
roteins (50 g) were separated by sodium dodecyl sulfate
olyacrylamide gel electrophoresis and transferred onto a
itrocellulose transfer membrane (Schleicher Schuell, the
etherlands). After blocking in TBS-T (150 mmol/l NaCl,
0 mmol/l Tris, and 0.1% Tween 20, pH 7.4) containing
% skim milk, the membranes were incubated with anti-
odies against Akt1, phospho-Akt1, vascular endothelial
rowth factor (VEGF), or actin (Santa Cruz Biotechnology,
anta Cruz, California). Hybridizing bands were visualized
sing an ECL detecting kit (Amersham Pharmacia Biotech,
iscataway, New Jersey).
tatistical analysis. All data are presented as mean 
EM. The two-tailed, unpaired Student t test, or one-way
nalysis of variance was used to compare group means, and
ultiple comparisons were performed using Fisher post-hoc
est. A probability value of p  0.05 was considered to be
tatistically significant. All statistical analysis was performed
sing StatView 4.5 software for Macintosh (SAS Institute
nc., Cary, North Carolina).
ESULTS
wine model. At four and eight weeks after the operation,
here was no difference in the body weight between two
roups. All animals (n 20) that were treated with saline or
-CSF survived throughout the study. The numbers of
hite blood cells and granulocytes at preoperation and one
nd four weeks after the operation were no different be-
ween two groups. The serum levels of creatine kinase-MB
soenzyme and cardiac troponin I at one and four weeks
fter the operation were within normal ranges, and no
ignificant differences were detected between two groups
data not shown), indicating that MI was not induced by the
peration. No differences were found in the serum levels of
nterleukin (IL)-1-beta and IL-6 before surgery or at and
our and eight weeks after the operation between the two
roups (data not shown).
chocardiographic analysis. We evaluated LV function
nd size by echocardiography before surgery and four and
Table 1. Echocardiographic Data
Control (n  10)
Pre 4 Weeks 8
LVEDA (cm2) 9.9  1.5 11.1  2.0 1
LVESA (cm2) 6.4  1.2 7.3  1.3
FAC (%) 35.5  6.0 34.1  2.7 3
IVSTd (mm) 5.3  0.3 5.2  0.3
PWTd (mm) 5.5  0.2 5.0  0.9
At preoperation (Pre), 4 weeks, and 8 weeks after the opera
end-systolic area (LVESA), fractional area change (FAC),
ventricular posterior wall thickness in diastole (PWTd) at the
B-mode. The average of three measurements was used for analyight weeks after the operation. Slight LV dilation and wall
v
ahinning with decreased contraction at the LCX region
ere recognized at 4 weeks after the operation (Table 1).
At eight weeks after the operation (four weeks after saline or
-CSF treatment), LV dilation became more prominent
LVEDA, 12.9  2.4 cm2; LVESA, 9.0  1.7 cm2) and LV
unction was worse in control group (FAC, 30.1  4.2%;
able 1). Dobutamine stress echocardiography demonstrated
hat regional contractility of the ischemic wall showed the
iphasic response to 10  and 40  of DOB at four weeks after
he operation (11.1  1.5% at rest; 14.5  2.1% at 10 ; 5.1
1.8% at 40 ), suggesting ischemic but viable myocardium.
t eight weeks after the operation (four weeks after saline or
-CSF treatment), however, there were significant differences
n the two groups. Left ventricular dilation was less in G-CSF
roup (LVEDA, 11.1  1.5 cm2; LVESA, 7.2  1.1 cm2)
han in the control group, and LV function was better in
-CSF group (FAC, 35.1 3.3%) than control group (Table
). Furthermore, at eight weeks after the operation, regional
ontractility of the ischemic region at rest and under stress with
OB were significantly larger in the G-CSF group than the
ontrol group (control, 11.9  2.8% vs. G-CSF 18.5  2.7%
t rest; control, 16.7 2.3% vs. G-CSF, 23.7 3.2% at 10 
igure 1. Regional contractility of ischemic wall. Regional contractility of
schemic (left circumflex coronary artery) wall was determined at eight weeks.
ach measurement was performed without or with continuous infusion of 10
g/kg/min (10 ) and 40 g/kg/min (40 ) of dobutamine to evaluate the
G-CSF (n  10)
eks Pre 4 Weeks 8 Weeks
2.4 9.4  1.5 11.4  2.4 11.1  1.5*
1.7 6.2  1.1 7.7  1.7 7.2  1.1*
4.2 34.6  3.4 32.8  8.0 35.1  3.3*
0.3 5.5  0.2 5.2  0.3 5.2  0.3
0.4 5.3  0.3 4.4  0.4 4.4  0.4
eft ventricular end-diastolic area (LVEDA), left ventricular
entricular septum thickness in diastole (IVSTd), and left
of midpapillary muscles in short-axis view were measured by







interviable ischemic myocardium. The average of three measurements was used for
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February 21, 2006:842–9 Effects of G-CSF on Chronic Myocardial Ischemiaf DOB; control, 5.0  2.2% vs. G-CSF, 12.9  4.5% at 40
of DOB) (Fig. 1).
ardiac catheter study. At four weeks after the implanta-
ion of ameroid constrictor, LCX was completely occluded
nd marked collateral flow was supplied from the left anterior
escending artery. Blood pressure was no different between
wo groups at preoperation or at four weeks or eight weeks
fter the operation. The LVEDP, dp/dt, and dp/dt were
o different between two groups at four weeks after the
peration (Table 2). At eight weeks after the operation,
owever, LVEDP was significantly lower in the G-CSF
roup than in the control group (Table 2).
istological analysis. The heart weight to body weight
atio was significantly larger in control group than G-CSF
roup at four weeks after the treatment (control, 6.3  0.6
/kg vs. G-CSF, 5.6  0.2 g/kg; p  0.05). van Gieson
taining revealed that there was less fibrosis in the heart of
he G-CSF group than control group at the ischemic region
Table 2. Hemodynamic Parameters by Cardiac
Control (n 
4 Weeks
dp/dt (mm Hg/s) 1,067  141 1
dp/dt (mm Hg/s) 1,580  179 1
LVEDP (mm Hg) 11.2  1.9
4 and 8 weeks after operation, cardiac catheter study was pe
of three measurements was used for analysis. Results are givigure 2. Fibrosis area of ischemic myocardium. Ischemic areas of control grou
B) were stained by van Gieson. Bar indicates 50 m. (C) The average of fibroticFigs. 2A to 2C). In the nonischemic region, there was no
ifference in fibrosis between two groups.
Because G-CSF has been reported to induce angiogenesis
24,25), we examined the number of vessels in ischemic
yocardium. There were more vWF-positive vessels at the
schemic region in the G-CSF group than the control group
Figs. 3A to 3C). In nonischemic region, there was no
ifference in vessel numbers between two groups.
Because it is well known that apoptotic cell death
ontributes to progression of cardiac remodeling in post-MI
eart and failing heart (26), we next measured the number of
poptotic cells in the ischemic myocardium using TUNEL
ssay. The number of TUNEL-positive cells in the ischemic
egion was smaller in the G-CSF group than the control group
control, 0.066  0.006 vs. G-CSF, 0.044  0.008%, p 
.05) at four weeks after the treatment (Figs. 4A and 4B).
ost of TUNEL-positive cells were infiltrated blood cells, and
part of TUNEL-positive cells were vascular cells (Fig. 4A).
heterization
G-CSF (n  10)
eeks 4 Weeks 8 Weeks
 60 996  90 1,158  88
 188 1,763  124 1,796  142
 2.0 9.0  1.0 3.7  0.7*
d. dp/dt, dp/dt, and LVEDP was measured. The average





7.2p (A) and granulocyte colony-stimulating factor (G-CSF)-treated group
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Effects of G-CSF on Chronic Myocardial Ischemia February 21, 2006:842–9lmost all vascular cells positive for TUNEL expressed vWF,
uggesting that apoptotic cells in the vessel were ECs. The
umber of TUNEL-positive ECs was significantly smaller in
he G-CSF treatment group (5.8  1.3%) than in the control
roup (9.4  0.7%, p  0.05) (Figs. 4C and 4D). The
UNEL-positive cardiomyocytes were not detected in the
schemic region.
ctivity and expression of Akt1 and VEGF. Because
kt1 has been reported to play an important role in cell
urvival and angiogenesis (27) and we have reported that Akt1
s activated in the infarcted heart after G-CSF treatment (16),
e examined the activity of Akt1 in ischemic myocardium.
estern blot analysis demonstrated that the level of phosphor-
lated Akt1 was lower in ischemic myocardium than in
ham-operated myocardium (Figs. 5A and 5B). However, we
ould not demonstrate the cell types in which Akt1 was
ctivated by G-CSF in the present study. The G-CSF treat-
ent attenuated the down-regulation of Akt1 activity in the
schemic region (Figs. 5A and 5B). Vascular endothelial
rowth factor, a main member of angiogenic growth factor
amily, induces proliferation and survival of ECs (28). There
as no significant difference in the expression level of VEGF
t four weeks after the treatment between the G-CSF treat-
igure 3. Number of vessels. Endothelial cells of ischemic area of con
roup (B) were identified immunohistochemically using anti-von Willebr
re given as mean  SEM (n  10 each group). *p  0.05.ent group and the control group (Figs. 5C and 5D). bISCUSSION
hronic myocardial ischemia is a clinical situation that char-
cterizes dysfunctional-but-viable myocardium as a result of an
xygen shortage due to a chronic or repetitive underperfusion
ccompanied by a limited coronary flow reserve (2). It has been
uggested that the underperfused myocardium can retain its
iability by reducing its contraction and that LV function can
e recovered by restoring myocardial oxygen supply or reducing
yocardial oxygen demand. Although chronic myocardial
schemia is viewed as an adaptive response to maintain cardi-
myocyte viability in the setting of reduced blood flow, fibrosis
s increased in ischemic myocardium (2,29,30). The beneficial
ffects of G-CSF on acute MI have been demonstrated, but its
ffects on chronic ischemic heart disease have not been deter-
ined. In the present study, we demonstrated that the
-CSF treatment also is effective on chronic myocardial
schemia. Treatment using G-CSF prevented cardiac
ysfunction and remodeling after chronic ischemia in-
uced by ameroid constrictors in a swine model. Stress
chocardiography revealed that G-CSF ameliorates the
egional contractility of chronic myocardial ischemia.
reatment using G-CSF decreased myocardial fibrosis
nd endothelial cell death in the ischemic region possibly
roup (A) and granulocyte colony-stimulating factor (G-CSF)-treated
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February 21, 2006:842–9 Effects of G-CSF on Chronic Myocardial IschemiaIn our echocardiographic studies at four weeks after the
reatment, we found that LV function was significantly
etter in the G-CSF group than in the control group.
obutamine stress echocardiography is used as a diagnostic
ool to noninvasively detect coronary artery stenosis and
ifferentiate viable from nonviable infarcted myocardium
31). Low-dose DOB improves wall thickening in the
schemic region and enhances echocardiographic detection
igure 4. Apoptosis of ischemic myocardium. Apoptotic cells of isch
eoxynucleotidyl transferase-mediated deoxyuridine triphosphate-digoxige
UNEL-positive cells. Bar indicates 30 m. (B) The percentage of the n
illebrand factor (vWF)- and TUNEL-positive cells. Bar indicates 5
UNEL-positive cells. Results are given as mean  SEM. *p  0.05.f contractile reserve in viable ischemic myocardium, and iigh-dose DOB induces ischemia and deteriorates wall
otion of ischemic myocardium (32). Because the biphasic
esponse is used as a marker of both viability and inducible
schemia in the regions with viable myocardium, DOB
tress echocardiography is useful to evaluate the therapeutic
ffects on regional contractility in chronic myocardial isch-
mia. The use of stress echocardiography in this study
learly demonstrated the beneficial effects of G-CSF on the
area at eight weeks after the operation were identified by terminal
ick end labeling (TUNEL) staining. (A) A representative photograph of
r of apoptotic cells in total cells. (C) Representative photographs of von
. (D) The percentage of vWF- and TUNEL-positive cells to totalemic
nin n
umbe
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Effects of G-CSF on Chronic Myocardial Ischemia February 21, 2006:842–9Histological analysis revealed that myocardial fibrosis was
ore prominent in the ischemic area compared with non-
schemic area and that the treatment with G-CSF signifi-
antly reduced fibrosis. The degree of fibrosis in nonisch-
mic area was not influenced by the treatment with G-CSF.
igure 5. Akt1 activity and vascular endothelial growth factor (VEGF)
xpression in myocardium. Whole tissue lysates were extracted from
yocardium of sham-operated swine and ischemic myocardium of oper-
ted swine, and subjected to Western blot analysis. (A) The membranes
ere incubated with antibodies against Akt1 and phospho-Akt1. Results
re representative of five independent experiments. (B) Quantitative
nalysis of Akt1 activity. Results are given as mean  SEM. (C) A
epresentative photograph of VEGF expression. Results are representative
f three independent experiments. (D) Quantitative analysis of VEGF
xpression. Results are given as mean  SEM. *p  0.05.he extent of myocardial fibrosis in the ischemic region was aess in the G-CSF group than in the control group.
lthough it is conceivable that the decrease in death of
ardiomyocytes is associated with the reduction in fibrosis,
-CSF also may modulate myocardial fibrosis through the
irect effects on cardiac fibroblasts. We actually found that
-CSF receptor exists on cardiac fibroblasts (17) and that
-CSF down-regulates the expression level of collagen I in
ardiac fibroblasts (Y. Qin et al, unpublished data, 2005). In
he hearts after MI, the cardiac interstitium exhibits inflam-
atory changes, leading to increased amount of fibrosis
33). It has been reported that inflammatory cytokines such
s IL-1-beta, IL-6, and tumor necrosis factor- are in-
olved in the generation of ischemic cardiomyopathy, in-
luding ventricular dilatation, depressed contractility, and
brosis (34). Although there were no differences in serum
evels of IL-1-beta and IL-6 before surgery and at four and
ight weeks after the operation between the two groups, it
emains to be determined whether expressions of inflam-
atory cytokines are increased in the heart.
The vessel numbers in the ischemic myocardium were
arger in the G-CSF treatment group than in the control
roup. These results suggest that G-CSF ameliorates isch-
mia by increasing vessel numbers in chronic myocardial
schemia. It has been reported that the mobilization of bone
arrow cells, including EPCs, are induced by G-CSF and
hat these cells may be involved in an increase in vessel
umber (9). We also observed the increase in vessel number
n the heart of acute MI by treatment with G-CSF (14).
reatment using G-CSF decreased the number of apoptotic
Cs in the ischemic myocardium. An increase in the vessel
umber, partly because of a decrease in dead ECs, may
esult in prevention of fibrosis and cardiac dysfunction.
lthough we could not detect a significant decrease in
poptotic cardiomyocytes by the G-CSF treatment, our
esults suggest that a G-CSF-induced increase in the vessel
umber may prevent cardiomyocyte death in chronically
schemic myocardium.
In ischemic myocardium, the activity of Akt1 was de-
reased and its activity was increased by the treatment with
-CSF. Akt1 has been reported to play a critical role in
urvival of cells, including ECs and cardiomyocytes (27,35).
herefore, there is a possibility that G-CSF could prevent
poptosis of cardiomyocytes even in a chronic ischemia
odel because G-CSF attenuated the down-regulation of
kt1 activity in the ischemic region. Because immunohis-
ochemical analysis using anti-phospho Akt1 antibody did
ot work well, we could not identify in which cell types
kt1 activity was increased by G-CSF. Further studies are
eeded to elucidate the role of Akt1 activation induced by
-CSF in chronic myocardial ischemia. G-CSF is known
o mobilize hematopoietic stem cells and EPCs into the
schemic myocardium, leading to angiogenesis. We have not
xamined whether G-CSF-induced mobilization of these
ells plays an important role in the beneficial effects, but
here is a possibility that both direct effects on myocardium
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February 21, 2006:842–9 Effects of G-CSF on Chronic Myocardial Ischemiaells may be involved in the beneficial effects of G-CSF on
hronic myocardial ischemia.
Although we have demonstrated that G-CSF has bene-
cial effects on chronic myocardial ischemia restricted to
CX region in the present study, G-CSF seems to have
ame antiapoptotic, antifibrotic, and angiogenic effects
herever the chronic ischemic region exists in myocardium.
here are many patients with global ischemic cardiomyop-
thy in whom the culprit lesions of coronary arteries are not
ligible for percutaneous coronary intervention in the clin-
cal setting. The use of G-CSF may become a promising
herapy for those patients.
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